Further Accelerating Cell Line Development and Reducing CMC Timeline to 3 Months from DNA to IND: the Journey from COVID to Non-COVID Programs
Sam Zhang, Kee Wee Tan, Junghao Wang, Weichang Zhou
WuXi Biologics, Waigaoqiao Free Trade Zone, Shanghai, China
|Since the COVID-19 outbreak, unconventional cell line development (CLD) strategies have been employed to enable development of SARS-CoV-2-neutralizing antibodies at expedited speed. In this work, we summarize the accelerated development of a total of seven antibody programs, some of which have received emergency use authorization (EUA) approval in less than two years.